middle.news

EVE Launches Dyspro™ Distribution via TeleDocs to Tackle Women’s Health Market

8:30am on Monday 22nd of September, 2025 AEST Healthcare
Read Story

EVE Launches Dyspro™ Distribution via TeleDocs to Tackle Women’s Health Market

8:30am on Monday 22nd of September, 2025 AEST
Key Points
  • Dyspro™ manufactured at Australian GMP-certified facility
  • Available for prescription through TeleDocs telehealth network
  • Targets dysmenorrhoea and endometriosis with large unmet medical needs
  • Global treatment market expected to exceed USD 20 billion by 2035
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Eve Health (ASX:EVE)
OPEN ARTICLE